+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Sale

Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016490
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gabapentin market is undergoing structural transformation as therapeutic applications expand and regulatory, supply chain, and technological shifts reshape the competitive environment. Senior decision-makers must act on comprehensive market analysis to align business strategy with evolving sector requirements and capitalize on emerging opportunities.

Market Snapshot: Gabapentin Market Insights

The gabapentin market grew from USD 2.32 billion in 2024 to USD 2.43 billion in 2025. It is projected to maintain growth at a CAGR of 4.39%, reaching USD 3.01 billion by 2030. This sustained development reflects increasing demand for robust neuropathic pain management, ongoing scientific advancement, and an active competitive landscape. New product formulations, improved patient stratification methods, and regulatory interventions are shaping a strategically significant environment for pharmaceutical stakeholders.

Scope & Segmentation of the Gabapentin Market

This comprehensive analysis segments the gabapentin market across key dimensions, supporting a targeted approach to market access and innovation:

  • Route of Administration: Oral products and parenteral solutions address diverse therapeutic scenarios.
  • Formulation: Both branded and generic offerings are assessed, highlighting lifecycle management and competition.
  • Dosage Form: Options include capsules (with both hard and soft gelatin types), oral solutions, and tablet forms such as extended and immediate release, offering choice for titration, adherence, and patient demographics.
  • Distribution Channel: Pathways include hospital, online, and retail pharmacies, each with unique access and service profiles for prescribers and patients.
  • End User: Clinics, home care providers, and hospitals present differentiated demand and operational requirements across patient care settings.
  • Indication: Epilepsy, neuropathic pain (frequently sub-categorized for diabetic neuropathy and postherpetic neuralgia), and restless leg syndrome are core therapeutic areas, driving product and portfolio strategies.
  • Geographical Coverage: Americas (with drilled-down analysis across U.S. states, plus Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (highlighting regulatory variance, modernizing systems, and key countries), and Asia-Pacific (spanning established and emerging growth hubs such as China, India, Japan, and Southeast Asia).
  • Company Coverage: Detailed trends and developments are tracked for major players including Teva Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., and Lupin Ltd.

Key Takeaways for Strategic Decision-Makers

  • Novel controlled-release technologies and digital health programs are enhancing adherence and patient outcomes across multiple care settings.
  • Patient stratification through pharmacogenomic insights is supporting advancements in personalized dosing and risk management, particularly for complex pain conditions.
  • Regional regulatory adaptation and channel optimization remain pivotal as manufacturers navigate pricing dynamics and shifting healthcare policies worldwide.
  • Pipeline innovation is centered on next-generation analogs and prodrugs, aiming to address unmet needs and expand the therapeutic footprint of gabapentin beyond established indications.
  • Competitive strategies now blend product innovation with digital patient engagement and sustainability initiatives across the pharmaceutical supply chain.

Tariff Impact on Raw Material Sourcing and Manufacturing Expenditure

The implementation of new US tariff structures in 2025 is set to influence cost frameworks for gabapentin, especially in raw material imports and downstream production. Suppliers are evaluating local synthesis and partnership models to maintain cost competitiveness while absorbing increased compliance and labor expenses. Flexible supply chain strategies are critical for responding to regulatory changes and maintaining operational resilience during this period of tariff adjustment.

Gabapentin Market Assessment: Methodology & Data Sources

This report integrates leading qualitative and quantitative research methods. Data sources include interviews with industry executives, clinicians, regulatory experts, and supply chain professionals. Supporting research leverages peer-reviewed studies, regulatory filings, patent analysis, corporate disclosures, and market intelligence from associations and trade reports. Analytical methods encompass competitor benchmarking, segmentation matrix evaluation, and scenario planning for regulatory impact.

Why This Gabapentin Market Report Matters

  • Enables strategic planning by delivering actionable, segment-specific market intelligence to inform investment and product strategy.
  • Supports operational readiness by outlining risk-adjusted approaches to supply chain and regulatory disruption.
  • Equips leadership with a data-driven foundation for competing in established and emerging regional markets, tailored to evolving patient and provider needs.

Conclusion

The gabapentin market is evolving through a combination of scientific, regulatory, and commercial factors. Senior decision-makers equipped with proven data and actionable insights can navigate complexity, capture emerging opportunities, and ensure resilient business growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of patented extended-release gabapentin formulations in neuropathic pain management
5.2. Escalating price competition among generic gabapentin manufacturers affecting market margins
5.3. Emerging clinical evidence supporting gabapentin use in treating fibromyalgia and off-label conditions
5.4. Regulatory agencies intensifying monitoring of gabapentin prescribing practices to curb misuse
5.5. Integration of digital adherence tools to optimize gabapentin therapy outcomes in chronic pain patients
5.6. Strategic partnerships between pharma and biotech firms to develop gabapentin combination therapies with improved efficacy
5.7. Supply chain innovations reducing lead times and ensuring consistent availability of gabapentin generics globally
5.8. Personalized medicine approaches leveraging genetic profiling to tailor gabapentin dosing regimens
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gabapentin Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Gabapentin Market, by Formulation
9.1. Introduction
9.2. Branded
9.3. Generic
10. Gabapentin Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.2.1. Hard Gelatin
10.2.2. Soft Gelatin
10.3. Oral Solution
10.4. Tablets
10.4.1. Extended Release
10.4.2. Immediate Release
11. Gabapentin Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gabapentin Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Gabapentin Market, by Indication
13.1. Introduction
13.2. Epilepsy
13.3. Neuropathic Pain
13.3.1. Diabetic Neuropathy
13.3.2. Postherpetic Neuralgia
13.4. Restless Leg Syndrome
14. Americas Gabapentin Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Gabapentin Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Gabapentin Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Ltd.
17.3.2. Viatris Inc.
17.3.3. Apotex Inc.
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd.
17.3.6. Cipla Ltd.
17.3.7. Zydus Lifesciences Ltd.
17.3.8. Torrent Pharmaceuticals Ltd.
17.3.9. Alembic Pharmaceuticals Ltd.
17.3.10. Lupin Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GABAPENTIN MARKET: RESEARCHAI
FIGURE 28. GABAPENTIN MARKET: RESEARCHSTATISTICS
FIGURE 29. GABAPENTIN MARKET: RESEARCHCONTACTS
FIGURE 30. GABAPENTIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. CANADA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. CANADA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 118. CANADA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 119. CANADA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 120. CANADA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 121. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. CANADA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. CANADA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. CANADA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 128. CANADA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 129. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. MEXICO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. MEXICO GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 136. MEXICO GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 137. MEXICO GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. MEXICO GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 221. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. GERMANY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. GERMANY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 228. GERMANY GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 229. GERMANY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 239. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. FRANCE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 244. FRANCE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 245. FRANCE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. FRANCE GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 275. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 278. ITALY GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 279. ITALY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 280. ITALY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 281. ITALY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 282. ITALY GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 283. ITALY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 284. ITALY GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 285. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ITALY GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. ITALY GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. ITALY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. ITALY GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. ITALY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 292. ITALY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 293. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. SPAIN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. SPAIN GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. SPAIN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. SPAIN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SPAIN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 300. SPAIN GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 301. SPAIN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SPAIN GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SPAIN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 346. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 348. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 350. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 352. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 354. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 356. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 358. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 360. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 361. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 362. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 363. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 364. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 365. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 366. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 367. DENMARK GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 368. DENMARK GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 369. DENMARK GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 370. DENMARK GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 371. DENMARK GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 372. DENMARK GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 373. DENMARK GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 374. DENMARK GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLIO

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Gabapentin market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Lupin Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.01 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Gabapentin Global Market Report 2025 - Product Image

Gabapentin Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Gabapentin - Global Strategic Business Report - Product Image

Gabapentin - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From

About the Gabapentin Market

Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and brand-name forms. It is available in capsule, tablet, and oral solution forms. It is also available as an extended-release tablet, which is taken once daily. The market for Gabapentin is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the companies in the market include Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.